S aureus

The US Food and Drug Administration has accepted the filing of The Medicines Company’s (MDCO’s) new drug application (NDA) for oritavancin, an investigational intravenous antibiotic, with priority review.

MDCO is seeking approval for Oritavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), administered as a single dose.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The NDA is based on data secured from two Phase III clinical trials, SOLO I and SOLO II, which were carried out under a special protocol assessment (SPA) agreement with the FDA.

Phase III trials assessed the efficacy and safety of a single 1,200mg dose of oritavancin compared with seven to ten days of twice-daily vancomycin in adults with ABSSSI, including infections caused by MRSA.

The combined SOLO studies were carried out in about 1,959 patients (modified intent-to-treat population, or mITT), with 405 of the patients suffering from an ABSSSI with a documented MRSA infection.

"We believe that upon approval, oritavancin, administered as a single dose for the treatment of ABSSSI, will offer new options for both physicians and their patients for the treatment of these infections."

The FDA designated oritavancin as a qualified infectious disease product (QIDP) in December 2013.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The designation provides oritavancin priority review as well as an additional five years of exclusivity upon approval of the product for the treatment of ABSSSI.

Under priority review, FDA takes action on the application within six months, compared with ten months under standard review.

The FDA assigned a prescription drug user fee act (PDUFA) action date of 6 August 2014.

The Medicines Company vice-president and medical director of infectious disease care Matthew Wikler sai: "We believe that upon approval, oritavancin, administered as a single dose for the treatment of ABSSSI, will offer new options for both physicians and their patients for the treatment of these infections."

Image: Scanning electron micrograph shows a strain of Staphylococcus aureus bacteria. Photo: courtesy of Raeky.